交易中 09-16 15:17:45 美东时间
-0.028
-1.18%
HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $13 to $9.
08-17 01:28
Rani Therapeutics Holdings, Inc. : H.c. Wainwright Cuts Target Price to $9 From...
08-16 18:08
Rani Therapeutics press release (NASDAQ:RANI): Q2 GAAP EPS of -$0.26. Cash, cash equivalents and marketable securities as of June 30, 2024 totaled $30.9M, compared to $48.5M for the year ended Decembe...
08-08 01:31
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-07 21:50
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.32) by 18.75 percent. This is a 29.73 percent increase over losses of $(0.37) per
08-07 05:02
Rani Therapeutics Holdings Inc - Look Forward to Initiating Phase 1 Study for R...
08-07 04:42
Rani Therapeutics Holdings Inc : Oppenheimer Initiates Coverage WithOutpe...
08-02 20:22
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered ...
07-22 20:30
Rani Therapeutics Holdings - After Evaluating Cash Position, Business, Elected ...
07-13 05:22
Rani Therapeutics Holdings Inc - Had Recently Engaged in Discussions With Vario...
07-13 05:21